Results 21 to 30 of about 2,191 (125)

Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report. [PDF]

Thorac Cancer
Serial re‐biopsy in EGFR‐mutant NSCLC revealed sequential acquired EGFR T790M, MET c.3010C>G exon 14‐related alteration, and RET‐CCDC6 fusion. Mechanism‐guided therapy with almonertinib, almonertinib plus savolitinib, and later selpercatinib plus almonertinib with local radiotherapy achieved prolonged disease control, with survival approaching 50 ...
Zhu Y, Wang C, Hu NL, Wang DH, Wu SK.
europepmc   +2 more sources

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program

Therapeutic Advances in Medical Oncology, 2021
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their ...
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M. S. Hashemi, Florian Huemer, Anders Vikström, Martin Wermke, Gudrun Absenger, Alfredo Addeo, Shantanu Banerji, Antonio Calles, Stephen Clarke, Massimo Di Maio, Alice Durand, Michaël Duruisseaux, Malinda Itchins, Okko-Sakari Kääränien, Florian Krenn, Eckart Laack, Adrianus Johannes de Langen, Katja Mohorcic, Georg Pall, Antonio Passaro, Gerald Prager, Achim Rittmeyer, Jeffrey Rothenstein, Michael Schumacher, Ewald Wöll, Arschang Valipour   +32 more
doaj   +1 more source

Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in RET fusion–positive non–small cell lung cancer: a case report

Frontiers in Oncology, 2023
IntroductionRearranged during transfection (RET) gene rearrangements occur in 1%–2% of non–small cell lung cancer (NSCLC). Because of the results of the study LIBRETTO-001, selpercatinib has been approved as the first-line treatment for patients with RET
Daniela Scattolin, Daniela Scattolin, Elena Scagliori, Antonio Scapinello, Alberto Fantin, Valentina Guarneri, Valentina Guarneri, Giulia Pasello, Giulia Pasello   +8 more
doaj   +1 more source

Unusual increase in carcinoembryonic antigen despite response to selpercatinib in two patients with medullary thyroid cancer

European Thyroid Journal, 2023
Introduction: Serum calcitonin (CT) and carcinoembryonic antigen (CEA) are valuable tumour markers in patients with medullary thyroid carcinoma (MTC). Both markers most often evolve in parallel after treatment.
Stéphane Bardet, Renaud Ciappuccini, Livia Lamartina, Sophie Leboulleux   +3 more
doaj   +1 more source

Current Guidelines for Management of Medullary Thyroid Carcinoma [PDF]

Endocrinology and Metabolism, 2021
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular cells. The diagnostic and therapeutic strategies for the condition are different from those used for well-differentiated thyroid cancer.
Mijin Kim, Bo Hyun Kim
doaj   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data [PDF]

Basic Clin Pharmacol Toxicol
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
van Elp G, Borg M, Bos J, Schuiling‐Veninga C, Taxis K, Jansman F.   +5 more
europepmc   +2 more sources

A case of organizing pneumonia in rearranged during transfection fusion‐positive lung adenocarcinoma treated with selpercatinib

Thoracic Cancer
Selpercatinib is the first targeted therapy for rearranged during transfection (RET) fusion‐positive unresectable non‐small‐cell lung cancer (NSCLC).
Hiroki Ohkoshi, Masafumi Saiki, Nozomu Takahashi, Kenta Homma, Satoshi Furuya, So Shimamura, Chisa Omori, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima   +10 more
doaj   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Acute severe hypocalcaemia after initiation of a selective RET-inhibitor in medullary thyroid cancer

Endocrine Oncology
Medullary thyroid cancer (MTC) is a rare subtype of thyroid cancer originating from parafollicular C-cells of the thyroid. Tyrosine kinase inhibitors are used to treat patients with advanced MTC.
Leslie Cheng, Syeda Khadijah Ghaznavi, Jessica Stevens, Sonja Hoy, Kee Howe Wong, Tass Malik, Kate Newbold, Daniel Morganstein   +7 more
doaj   +1 more source

Genetic Mutations in Recurrent/Metastatic Papillary Thyroid Carcinoma

The Laryngoscope, EarlyView.
We investigated the mutational landscape and prognostic implications of recurrent/metastatic papillary thyroid carcinoma using nationwide C‐CAT data from 348 patients. CDKN2A, KMT2D, and concurrent TERT/BRAF mutations were independently associated with poorer overall survival, highlighting the potential prognostic value of comprehensive genomic ...
Hiromi Nagano, Satoshi Kiyama, Takayuki Kyutoku, Masaru Yamashita   +3 more
wiley   +1 more source